Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing.
暂无分享,去创建一个
Jeremy Purvis | Ravi Radhakrishnan | R. Radhakrishnan | J. Purvis | Andrew J Shih | Andrew J. Shih | Jeremy Purvis | Ravi Radhakrishnan
[1] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[2] Jeremy Purvis,et al. Role of Network Branching in Eliciting Differential Short‐Term Signaling Responses in the Hypersensitive Epidermal Growth Factor Receptor Mutants Implicated in Lung Cancer , 2008, Biotechnology progress.
[3] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[4] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[5] D. Haber,et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. , 2006, Cancer cell.
[6] Matthew Meyerson,et al. Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 , 2004, Cancer Research.
[7] H. W. Veen,et al. An ABC transporter with a secondary-active multidrug translocator domain , 2003, Nature.
[8] Jian Hui Wu,et al. Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations , 2006, Proteins.
[9] K. H. Lee,et al. The statistical mechanics of complex signaling networks: nerve growth factor signaling , 2004, Physical biology.
[10] M Paesmans,et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.
[11] P. De Camilli,et al. Endocytosis proteins and cancer: a potential link? , 1998, Trends in cell biology.
[12] Jeremy Purvis,et al. A Multiscale Computational Approach to Dissect Early Events in the Erb Family Receptor Mediated Activation, Differential Signaling, and Relevance to Oncogenic Transformations , 2007, Annals of Biomedical Engineering.
[13] Mark von Zastrow,et al. Signal transduction and endocytosis: close encounters of many kinds , 2002, Nature Reviews Molecular Cell Biology.
[14] R. Radhakrishnan,et al. EFFICACY OF TYROSINE KINASE INHIBITORS IN THE MUTANTS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR: A MULTISCALE MOLECULAR/ SYSTEMS MODEL FOR PHOSPHORYLATION AND INHIBITION , 2007 .
[15] Y. Yarden,et al. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases , 2001, FEBS letters.
[16] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[17] J. Minna,et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. , 2007, Cancer cell.
[18] Andrea Richardson,et al. A role for the scaffolding adapter GAB2 in breast cancer , 2006, Nature Medicine.
[19] B. Kholodenko. Cell-signalling dynamics in time and space , 2006, Nature Reviews Molecular Cell Biology.
[20] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[21] S. Schmid,et al. Control of EGF Receptor Signaling by Clathrin-Mediated Endocytosis , 1996, Science.
[22] Ron Bose,et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. , 2008, Structure.
[23] G. V. Vande Woude,et al. BRAF and MEK Mutations Make a Late Entrance , 2006, Science's STKE.
[24] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[25] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[26] A. Ullrich,et al. Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors* , 2003, The Journal of Biological Chemistry.
[27] W. Park,et al. Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.
[28] E. Gilles,et al. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.
[29] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[30] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[31] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[32] G J Griffiths,et al. Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. , 2006, Systems biology.
[33] S. Parsons,et al. STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor* , 2003, The Journal of Biological Chemistry.
[34] G. Carpenter,et al. ErbB receptors: new insights on mechanisms and biology. , 2006, Trends in cell biology.
[35] H. Stenmark,et al. Defective downregulation of receptor tyrosine kinases in cancer , 2004, The EMBO journal.
[36] A. Citri,et al. EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.
[37] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[38] D. Haber,et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. , 2007, Cancer research.
[39] Salvatore Pece,et al. Endocytosis and cancer. , 2004, Current opinion in cell biology.
[40] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[41] “KMC-TDGL”—a coarse-grained methodology for simulating interfacial dynamics in complex fluids: application to protein-mediated membrane processes , 2006, Molecular physics.
[42] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[43] S. Kimura,et al. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. , 2003, The Biochemical journal.
[44] B. Kholodenko,et al. Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.
[45] B. Kholodenko,et al. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses , 2007, Molecular systems biology.
[46] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.